Piper Jaffray analyst Edward Tenthoff raised his price target for Aptevo Therapeutics to $11 after Q2 sales of the company’s prophylactic hemophilia B therapy Ixinity beat his estimate. The analyst increased his Ixinity sales forecast to $25M from $18M for 2018 and reiterates an Overweight rating on Aptevo Therapeutics.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.